لقاح جديد مضاد للبكتيريا الرئوية

A clinical study from "Merck" showed that a new vaccine against pneumococcal bacteria called Capvaxive provided strong and effective immune responses in children and adolescents with chronic illnesses or weakened immune systems, compared to the old vaccine PPSV23. The study, which included participants aged two to 18 years, indicated that the new vaccine covers a wide range of bacterial strains responsible for pneumonia, meningitis, and sepsis, which are diseases that pose a serious threat to vulnerable health groups. The results also showed that the vaccine is safe, with no serious side effects recorded during the trial period, enhancing the likelihood of its approval by regulatory authorities in the near future. Researchers confirmed that the introduction of this vaccine into national immunization programs could significantly reduce the burden of respiratory diseases and lower mortality and hospitalization rates, especially in communities lacking strong health systems or experiencing high rates of antibiotic-resistant bacterial infections.